XELOX方案一线化疗加卡培他滨维持治疗晚期胃癌的临床疗效分析

胃癌是危害国民身体健康的重大疾病之一,每年新发胃癌病例约40万,死亡人数约30万例,居恶性肿瘤第3位[1].多数胃癌患者初诊时即为局部晚期或存在远处转移,失去手术机会,即使是接受根治性切除术的胃癌患者,仍有40％～60％会出现疾病复发.对于这部分晚期胃癌患者,化疗仍是其主要的治疗手段[2].然而在过去30年中,胃癌的化疗研究进展缓慢,目前尚无标准方案.本研究尝试在卡培他滨联合奥沙利铂(XE-LOX方案)化疗的基础上应用卡培他滨维持化疗治疗晚期胃癌,取得初步良好疗效,现报告如下,供同行参考.

First line XELOX chemotherapy combined with subsequent capecitabine maintenance chemotherapy for patients with advanced gastric cancer: a clinical analysis of effectiveness

Objective To investigate the eurative effect and safety of oxaliplatin plus capecitabine with subsequent capecitabine maintenance chemotherapy for patients with advanced gastric cancer. Methods: A total of 32 patients were enrolled into this study, they received first line oxaliplatin plus capecitabine (XELOX) chemotherapy. Patients without tumor progression were assigned to the group with capecitabine maintenance chemotherapy. Results: The response rate (RR) of first-line chemotherapy was 46.9% (15/32); 26 patients entered the capecitabine maintenance chemotherapy group, RR was 26.9% (7/26). The median PFS of whole group was 8.9 months, 1 and 2 year survival rate were 56.2% (18/32) and 31.2% (10/32), respectively. The main adverse reactions were nausea, vomiting, diarrhea, bone marrow suppression, neurotoxicity and hand foot syndrome, which can be tolerated. Conclusion XELOX regimen chemotherapy followed by capecitabine maintenance therapy for advanced gastric cancer patients is effective and safe, while bring a certain degree of survival benefit.